Caribou Biosciences CEO, Rachel Haurwitz will talk CRISPR’s present and future applications at DisruptSF

Seven years ago, Rachel Haurwitz finished her last day as a student in the University of California laboratory where she helped conduct some of the pioneering research on the gene editing technology known as CRISPR, and became employee number one at Caribou Biosciences, a company founded to commercialize that research. In those seven years, the market for CRISPR applications has grown tremendously and Caribou Biosciences is at the forefront of the companies propelling it forward. Learn more about your ad choices. Visit podcastchoices.com/adchoices